An Open-Label Non-Interventional Evaluation of Efficacy of Symbicort Forte Turbuhaler 320/9 microg (Budesonide / Formoterol) and Symbicort Turbuhaler 160/4,5 microg (Budesonide / Formoterol)in Functional Status Improvement of Patients With Chronic Obstructive Pulmonary Disease (COPD).

Trial Profile

An Open-Label Non-Interventional Evaluation of Efficacy of Symbicort Forte Turbuhaler 320/9 microg (Budesonide / Formoterol) and Symbicort Turbuhaler 160/4,5 microg (Budesonide / Formoterol)in Functional Status Improvement of Patients With Chronic Obstructive Pulmonary Disease (COPD).

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Jan 2011

At a glance

  • Drugs Budesonide/formoterol (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 11 Feb 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top